Arrowhead Pharmaceuticals, Inc.

LSE:0HI3 Stock Report

Market Cap: US$2.5b

Arrowhead Pharmaceuticals Valuation

Is 0HI3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HI3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0HI3's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0HI3's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HI3?

Key metric: As 0HI3 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0HI3. This is calculated by dividing 0HI3's market cap by their current book value.
What is 0HI3's PB Ratio?
PB Ratio13.6x
BookUS$185.44m
Market CapUS$2.52b

Price to Book Ratio vs Peers

How does 0HI3's PB Ratio compare to its peers?

The above table shows the PB ratio for 0HI3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average41.8x
GNS Genus
2.3x37.2%UK£1.3b
OXB Oxford Biomedica
6.7x92.5%UK£441.8m
PRTC PureTech Health
1.4x-12.8%UK£358.7m
FARN Faron Pharmaceuticals Oy
156.6x29.8%UK£180.5m
0HI3 Arrowhead Pharmaceuticals
13.6x18.7%US$2.5b

Price-To-Book vs Peers: 0HI3 is good value based on its Price-To-Book Ratio (13.6x) compared to the peer average (41.8x).

Price to Book Ratio vs Industry

How does 0HI3's PB Ratio compare vs other companies in the GB Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
VAL ValiRx
0.3xn/aUS$1.24m
0HMP Bellerophon Therapeutics
0.1xn/aUS$489.31k
No more companies available in this PB range
0HI3 13.6xIndustry Avg. 3.2xNo. of Companies4PB01.63.24.86.48+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0HI3 is expensive based on its Price-To-Book Ratio (13.6x) compared to the UK Biotechs industry average (3.2x).

Price to Book Ratio vs Fair Ratio

What is 0HI3's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HI3 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio13.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0HI3's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HI3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$19.46
US$47.50
+144.2%
40.5%US$80.00US$24.00n/a14
Jan ’26US$18.35
US$47.50
+158.8%
40.5%US$80.00US$24.00n/a14
Dec ’25US$26.17
US$45.38
+73.4%
39.2%US$71.00US$23.00n/a13
Nov ’25US$19.63
US$47.29
+140.9%
37.0%US$71.00US$20.00n/a14
Oct ’25US$18.76
US$47.29
+152.1%
37.0%US$71.00US$20.00n/a14
Sep ’25US$23.40
US$47.21
+101.8%
37.3%US$71.00US$19.00n/a14
Aug ’25US$27.25
US$50.29
+84.5%
33.2%US$74.00US$27.00n/a14
Jul ’25US$25.80
US$52.43
+103.2%
37.2%US$90.00US$27.00n/a14
Jun ’25US$22.78
US$53.77
+136.1%
36.2%US$90.00US$27.00n/a13
May ’25US$23.12
US$53.66
+132.1%
34.5%US$90.00US$28.00n/a14
Apr ’25US$28.95
US$55.15
+90.5%
33.3%US$90.00US$28.00n/a13
Mar ’25US$35.55
US$55.15
+55.1%
33.3%US$90.00US$28.00n/a13
Feb ’25US$32.13
US$55.46
+72.6%
36.0%US$90.00US$27.00US$19.4613
Jan ’25US$30.78
US$53.29
+73.1%
39.6%US$90.00US$24.00US$18.3514
Dec ’24US$22.08
US$55.08
+149.5%
36.5%US$90.00US$24.00US$26.1713
Nov ’24US$25.13
US$55.93
+122.6%
34.7%US$90.00US$26.00US$19.6314
Oct ’24US$27.32
US$56.71
+107.6%
33.9%US$90.00US$27.00US$18.7614
Sep ’24US$28.06
US$58.54
+108.6%
32.0%US$90.00US$27.00US$23.4013
Aug ’24US$33.99
US$62.15
+82.9%
28.1%US$90.00US$27.00US$27.2513
Jul ’24US$35.52
US$61.77
+73.9%
28.4%US$90.00US$27.00US$25.8013
Jun ’24US$34.80
US$62.07
+78.4%
28.0%US$90.00US$27.00US$22.7814
May ’24US$35.75
US$61.14
+71.0%
28.8%US$90.00US$27.00US$23.1214
Apr ’24US$25.32
US$61.00
+140.9%
33.2%US$90.00US$21.00US$28.9514
Mar ’24US$32.67
US$63.62
+94.7%
29.2%US$90.00US$21.00US$35.5513
Feb ’24US$35.05
US$65.38
+86.5%
29.0%US$90.00US$22.00US$32.1313
Analyst Price Target
Consensus Narrative from 14 Analysts
US$46.93
Fair Value
57.4% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 02:38
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arrowhead Pharmaceuticals, Inc. is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Ying HuangBarclays
Jason Matthew GerberryBofA Global Research